Published in J Hepatol on June 01, 1999
Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology (2011) 5.06
NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest (2003) 3.69
Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A (2001) 2.93
Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med (2008) 2.14
S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev (2012) 1.82
S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci U S A (2006) 1.66
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Inflammation in alcoholic liver disease. Annu Rev Nutr (2012) 1.49
Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39
S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology (2009) 1.32
S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. Hepatology (2008) 1.30
Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology (2008) 1.27
Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol (2006) 1.17
Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. J Dig Dis (2012) 1.14
Treatment of alcoholic liver disease. Dig Dis (2005) 1.10
May oxidative stress contribute to autoimmune hepatitis pathogenesis, and can antioxidants be of value as adjuvant therapy for refractory patients? Dig Dis Sci (2013) 1.09
Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis (2009) 1.08
Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol (2014) 1.06
Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut (2002) 1.04
Lipid peroxide levels and antioxidant status in alcoholic liver disease. Indian J Clin Biochem (2005) 1.02
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
Mechanism for prevention of alcohol-induced liver injury by dietary methyl donors. Toxicol Sci (2010) 1.00
The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig Dis Sci (2008) 0.99
Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis. J Clin Invest (2004) 0.98
Impaired terminal differentiation of pulmonary macrophages in a Guinea pig model of chronic ethanol ingestion. Alcohol Clin Exp Res (2009) 0.98
Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection. Am J Physiol Gastrointest Liver Physiol (2010) 0.96
S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res (2011) 0.94
Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention. J Surg Res (2009) 0.94
Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. World J Gastroenterol (2014) 0.92
The induction of growth arrest DNA damage-inducible gene 45 beta in human hepatoma cell lines by S-adenosylmethionine. Am J Pathol (2007) 0.90
Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol (2006) 0.90
The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract (2006) 0.89
S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One (2010) 0.88
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Folate, alcohol, and liver disease. Mol Nutr Food Res (2012) 0.87
KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol (2013) 0.87
S-adenosylmethionine metabolism and liver disease. Ann Hepatol (2013) 0.86
Betulinic acid prevents alcohol-induced liver damage by improving the antioxidant system in mice. J Vet Sci (2013) 0.86
Oxidative stress and benefits of antioxidant agents in acute and chronic hepatitis. Hepat Mon (2012) 0.84
Targeting collagen expression in alcoholic liver disease. World J Gastroenterol (2011) 0.83
Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol (2014) 0.83
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Exp Mol Pathol (2012) 0.83
Vitamin-dependent methionine metabolism and alcoholic liver disease. Adv Nutr (2011) 0.83
Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol (2010) 0.82
Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood) (2015) 0.81
Aberrant hepatic methionine metabolism and gene methylation in the pathogenesis and treatment of alcoholic steatohepatitis. Int J Hepatol (2011) 0.81
Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci (2016) 0.81
Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol (2013) 0.80
Focus on: Alcohol and the liver. Alcohol Res Health (2010) 0.80
S-Adenosylmethionine regulates connexins sub-types expressed by hepatocytes. Eur J Cell Biol (2010) 0.80
Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1. Curr Drug Metab (2015) 0.79
Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol (2013) 0.79
Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III: Characterization of DDX3X as a target of S-adenosylmethionine. J Proteomics (2012) 0.79
S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One (2015) 0.79
Interactions of ethanol and folate deficiency in development of alcoholic liver disease in the micropig. Trans Am Clin Climatol Assoc (2002) 0.79
Synergistic protection by S-adenosylmethionine with vitamins C and E on liver injury induced by thioacetamide in rats. Free Radic Biol Med (2005) 0.79
Alcoholic liver disease patients treated with S-adenosyl-L-methionine: an in-depth look at liver morphologic data comparing pre and post treatment liver biopsies. Exp Mol Pathol (2013) 0.79
The methyl donor S-adenosylmethionine prevents liver hypoxia and dysregulation of mitochondrial bioenergetic function in a rat model of alcohol-induced fatty liver disease. Redox Biol (2016) 0.78
A Complex Multiherbal Regimen Based on Ayurveda Medicine for the Management of Hepatic Cirrhosis Complicated by Ascites: Nonrandomized, Uncontrolled, Single Group, Open-Label Observational Clinical Study. Evid Based Complement Alternat Med (2015) 0.78
Pharmacotherapy of acute alcoholic hepatitis in clinical practice. World J Gastroenterol (2014) 0.78
Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver (2016) 0.77
Treatment of decompensated alcoholic liver disease. Int J Hepatol (2011) 0.76
Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages. Gastroenterol Res Pract (2016) 0.75
Selection and Characteristics of Fermented Salted Seafood (jeotgal)-Originated Strains with Excellent S-adenosyl-L-methionine (SAM) Production and Probiotics Efficacy. Korean J Food Sci Anim Resour (2014) 0.75
Selection and characterization of Cheonggukjang (fast fermented soybean paste)-originated bacterial strains with a high level of S-adenosyl-L-methionine production and probiotics efficacy. J Med Food (2014) 0.75
Challenge for doctors and policy makers. BMJ (2006) 0.75
A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev Res (Phila) (2015) 0.75
Management of alcoholic hepatitis: Current concepts. World J Hepatol (2012) 0.75
Adipose tissue-liver axis in alcoholic liver disease. World J Gastrointest Pathophysiol (2016) 0.75
SAMe and HuR in liver physiology: usefulness of stem cells in hepatic differentiation research. Methods Mol Biol (2012) 0.75
Alterations in the glutathione metabolism could be implicated in the ischemia-induced small intestinal cell damage in horses. BMC Vet Res (2009) 0.75
S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry (2017) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Genomic mutation rates for lifetime reproductive output and lifespan in Caenorhabditis elegans. Proc Natl Acad Sci U S A (1997) 3.37
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol (2001) 2.73
Effects of somatostatin on renal function in cirrhosis. Gastroenterology (1992) 2.68
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Effective size of populations under selection. Genetics (1995) 2.54
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology (1995) 2.47
Local and remote sustained trigger point therapy for exacerbations of chronic low back pain. A randomized, double-blind, controlled, multicenter trial. Spine (Phila Pa 1976) (1997) 2.29
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther (1997) 2.13
Are avian blood parasites pathogenic in the wild? A medication experiment in blue tits (Parus caeruleus). Proc Biol Sci (2000) 2.12
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Fate of Bacillus sphaericus 1593 and 2362 spores used as larvicides in the aquatic environment. Appl Environ Microbiol (1984) 2.06
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology (1993) 1.97
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol (1999) 1.92
Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 1.91
Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol (2001) 1.89
Properties of spontaneous mutations affecting quantitative traits. Genet Res (1999) 1.88
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet (1989) 1.86
Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol (1986) 1.84
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Systematic review: hepatitis-associated aplastic anaemia--a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther (2009) 1.83
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med (1982) 1.79
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol (2000) 1.74
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74
Accounting for bias in estimates of the rate of polygenic mutation. Proc Biol Sci (1993) 1.71
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 1.68
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (1990) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med (1994) 1.66
Fulminant hepatic failure. Lancet (1997) 1.66
In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology (2001) 1.66
On the average coefficient of dominance of deleterious spontaneous mutations. Genetics (2000) 1.64
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology (1998) 1.60
Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology (1999) 1.59
Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis (1976) 1.59
Foreign body ingestion: management of 167 cases. World J Surg (1992) 1.58
Biological degradation of 2,4,6-trinitrotoluene. Microbiol Mol Biol Rev (2001) 1.58
Tonsillectomy and inflammatory bowel disease location. Eur J Gastroenterol Hepatol (1996) 1.57
Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet (1993) 1.57
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57
Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther (2007) 1.55
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol (1998) 1.55
Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology (1994) 1.54
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. J Hepatol (2000) 1.53
Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology (1990) 1.52
Effective size and polymorphism of linked neutral loci in populations under directional selection. Genetics (1998) 1.52
Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol (1994) 1.49
Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol (1998) 1.49
Cyclosporine-associated mutism in liver transplant patients. Neurology (1996) 1.49
A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol (2001) 1.49
Coprecipitation with lactose as a means of recovering the sporte-crystal complex of Bacillus thuringiensis. J Invertebr Pathol (1970) 1.48
Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the Mallory-Weiss syndrome. Am J Gastroenterol (1994) 1.48
Isolation of microorganisms for biological detoxification of lignocellulosic hydrolysates. Appl Microbiol Biotechnol (2003) 1.47
Limitations of laser-Doppler velocimetry and reflectance spectrophotometry in estimating gastric mucosal blood flow. Am J Physiol (1992) 1.43
Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology (1997) 1.43
Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology (1992) 1.42
Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology (1988) 1.40
Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes. Dig Dis Sci (1988) 1.40
Expression, tissue distribution and subcellular localization of dehydrin TAS14 in salt-stressed tomato plants. Plant Mol Biol (1994) 1.40
[Utility of analytical parameters in the diagnosis of liver disease]. An Med Interna (2007) 1.40
[Consensus on spontaneous bacterial peritonitis in liver cirrhosis: diagnosis, treatment, and prophylaxis]. Gastroenterol Hepatol (2001) 1.40